Table 3. In vivo actions of resolvin E series.
| Disease model | Action | Dosage (route) | Duration of postexposure | Reference |
|---|---|---|---|---|
| Resolvin E1 | ||||
| Skin (dorsal air pouch) | Reduces PMN infiltration | 100 ng per mouse (i.v.) | 4 h | Serhan et al. (2000, 2002) |
| Peritonitis | Reduces PMN infiltration and regulates chemokine/cytokine production | 300 ng per mouse (i.p.) | 4–24 h | Bannenberg et al. (2005) |
| 100 ng per mouse (i.v.) | 2 h | Arita et al. (2005a) | ||
| Reduces PMN infiltration | 10 ng per mouse (i.p.) | 2–4 h | Serhan et al. (2006a) | |
| Colitis | Decreases PMN recruitment and pro-inflammatory gene expression | 50 μg kg−1 (i.p.) on days −8, −1 and 0 before induction of colitis | 4–12 days | Arita et al. (2005c) |
| Improves survival | ||||
| Reduces weight loss | ||||
| Oral (periodontitis) | Reduces PMN infiltration, stops inflammation-induced tissue and bone loss | 4 μg per tooth (topical application, every other day) | 6 weeks | Hasturk et al. (2006) |
| Eye (retinopathy) | Reduces vaso-obliteration and neovascularization | 10 ng per day (i.p.), from postnatal day 6 to day 17 | 17 days | Connor et al. (2007) |
| Resolvin E2 | ||||
| Peritonitis | Reduces PMN infiltration | 10 ng per mouse (i.v., i.p.) | 2 h | Tjonahen et al. (2006) |
Abbreviation: PMN, polymorphonuclear leukocyte.